Results 171 to 180 of about 15,465 (199)

RETRACTION: Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison. [PDF]

J Dermatol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Baricitinib

Reactions Weekly
  +21 more sources

Baricitinib

Reactions Weekly, 2023
  +12 more sources

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial [PDF]

Lancet, The, 2018
© 2018 Elsevier Ltd Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with ...
Marta Mosca, Richard A Furie, Yoshiya Tanaka   +2 more
exaly   +3 more sources

Baricitinib

Reactions Weekly, 2022
  +9 more sources

Baricitinib

Reactions Weekly, 2018
Wie Tofacitinib ein Januskinase-Hemmer, kann Baricitinib bei der rheumatoiden Arthritis eingesetzt werden, wenn Methotrexat nicht genügend wirkt oder nicht vertragen wird. Das Nutzen-Risiko-Verhältnis einer langfristigen Verabreichung von Januskinase-Hemmern ist jedoch noch ungenügend definiert.
openaire   +2 more sources

Baricitinib

Reactions Weekly, 2021
openaire   +2 more sources